Charlotte Robinson

DocwireNews

Potassium adsorbents play a significant role in managing hyperkalemia, a major complication of chronic kidney disease (CKD). Both calcium polystyrene sulfonate (CPS) and sodium polystyrene sulfonate (SPS) have been shown to lower serum potassium levels, although their effects on mortality and rehospitalization rates have not been examined thoroughly. Meanwhile, sodium zirconium cyclosilicate (SZC) has emerged as a promising new potassium adsorbent.In a study published in Clinical Kidney Journal, Chikao Onogi, MD, PhD, and colleagues examined how mortality and hyperkalemia-associated hospitalization rates vary with the use of different potassium adsorbents. The retrospective study drew data from a Japanese medical claims database and included data on 36,690,000 patients from 449 hospitals dating from April 2008 to August 2021.The team identified 924,238 patients with CKD codes and selected those aged &ge;20 years. The study enrollees were prescribed potassium adsorbents (SZC, CPS, or SPS) during the 1-year observation period and received consecutive prescriptions for at least 100 days. There were 243 patients receiving SZC; 54,183 receiving CPS; and 18,692 receiving SPS. In each group, 65% to 66% were men and the age range was 72-74 years, with significant differences (P&lt;.001). Hypertension was common in all groups. About half of patients in each group had a history of heart failure (53%, 49%, and 44% in SZC, CPS, and SPS, respectively). The SZC group had a higher percentage of patients on maintenance hemodialysis (46.0% vs 8.2% and 13.0% for CPS and SPS, respectively).The primary outcome, a composite of mortality and hyperkalemia-associated hospitalization, was lower in the SZC group than in other groups (0.8% for SZC compared with 4.6% and 3.8% for CPS and SPS, respectively). Overall survival rates were &gt;80% during the observation period, and the SZC group had a significantly higher survival rate (P&lt;.001, log-rank test).The researchers also assessed prescription retention rates for patients prescribed renin-angiotensin-aldosterone system inhibitors (RAASi) at the beginning of the observation period. This was of interest because discontinuing RAASi contributes to increased mortality in patients with CKD. The SZC group had a much higher RAASi prescription continuation rate compared with the SPS group (P=.031). No major differences were found for the other combinations (P=.054 for SZC vs CPS and P=.092 for CPS vs SPS), but the SZC group had a lower discontinuation rate than the CPS group.Limitations of the study include its retrospective nature and the number of participants, which may have been insufficient. In addition, use of SZC is limited, so the number of deaths and hospitalizations among those using it may not be sufficiently observable. Finally, it would be preferable to include large numbers of patients when assessing discontinuation rates of RAASi to enable a more detailed discussion.The study&rsquo;s authors acknowledged that &ldquo;the high RAASi continuation rate in the SZC group might be a contributing factor for improvement of the primary outcome.&rdquo; However, they concluded that &ldquo;this real-world study demonstrated the therapeutic effect of SZC in reducing mortality and hyperkalemia-associated [hospitalizations].&rdquo;&nbsp;Source: <a href="https://doi.org/10.1093/ckj/sfae021" target="_blank" rel="noopener">Clinical Kidney Journal</a>

Eva Blondeaux, MD

Risk-Reducing Surgery Linked to Survival in Young BRCA Carriers

Genetics & Breast Cancer

Jordana Jampel

Successful HIV Viral Suppression With At-Home Administration

Modernization and the Rising Burden of IBD: New Insights From a Global Study

Gastroenterology

Latest News

Comparison of Potassium Adsorbents for Hyperkalemia

Hyperkalemia

Potassium adsorbents lower serum potassium levels but their effects on mortality and rehospitalization rates were unclear.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe